Please login to the form below

Not currently logged in
Email:
Password:

urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

Positive first-line phase 3 results for Tecentriq

Positive first-line phase 3 results for Tecentriq

advanced or metastatic urothelial carcinoma (mUC). Urothelial carcinoma is the most common type of bladder cancer, and accounts for around 90% of cases, with 30% of those considered to be advanced.

Latest news

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics